1	Power and sample sizes estimation in clinical trials with treatment switching in
2	intention-to-treat analysis: a simulation study
3	
4	Lejun Deng ^{1#} , Chih-Yuan Hsu ^{2,3#} , Yu Shyr ^{2,3*}
5	
6	¹ Montgomery Bell Academy, Nashville, TN, 37205, USA
7	² Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
8	³ Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232,
9	USA
10	*corresponding authors: Yu Shyr (<u>yu.shyr@vumc.org</u>)
11	# These authors contributed equally.
12	
13	
14	Abstract
15	Background: Treatment switching, also called crossover, is common in clinical trials because of
16	ethical concerns or other reasons. When it occurs and the primary objective is to identify treatment
17	effects, the most widely used intention-to-treat analysis may lead to underpowered trials.
18	Therefore, we plan to propose an approach to preview power reductions and to estimate sample
19	sizes required for the desired power when treatment switching occurs in the intention-to-treat
20	analysis.
21	Methods: We proposed a simulation-based approach and developed an R package to attain the
22	purpose.

23 **Results:** We simulated a number of randomized trials incorporating treatment switching and 24 investigated the impact of the relative effectiveness of the experimental treatment to the control, 25 the switching probability, the allocation ratio, and the switching time on power reductions and 26 sample sizes estimation. The switching probability and the switching time are key determinants 27 for significant power decreasing and thus sample sizes surging to maintain the desired power. The 28 sample sizes required in randomized trials absence of treatment switching varied from around 29 three-fourths to one-twelfths of the sample sizes required in randomized trials allowing treatment 30 switching as the probability of switched patients increased. The power reductions and sample sizes 31 increase with the decrease of switching time.

32 **Conclusions:** The simulation-based approach not only provides a preview for power declining but 33 also calculates the required sample size to achieve an expected power in the intention-to-treat 34 analysis when treatment switching occurs. It will provide researchers and clinicians with useful 35 information before randomized controlled trials are conducted.

36

37 Keywords

38 Crossover; intention-to-treat analysis; randomized controlled trials; treatment switching39

40 **1. Background**

Clinical trials are often used to assess the effectiveness of new treatments. The most reliable clinical trial is the randomized controlled trials (RCT). In an RCT, patients are randomly assigned to the control group, where they receive a placebo or an existing standard treatment, or the experimental group, where they receive the experimental treatment. For treatments against diseases like cancer, the effectiveness of the new treatment is determined by comparing the

46 observed survival time of patients in the experimental group to those in the control group. The 47 power of a statistical test, which is the probability to correctly tell if the experimental treatment is 48 better when it is truly better, is extremely important. Being able to correctly determine the 49 effectiveness of an experimental treatment gives justification for its production, allows for better 50 utilization of resources, and helps those who will benefit from the experimental treatment.

51

A common method used to interpret the data from a RCT is the intention-to-treat analysis (ITT). 52 The ITT analysis includes all patients with randomization in statistical analysis and compares their 53 54 responses to determine the effectiveness of the experimental treatment according to the treatment 55 group that was initially assigned to them, regardless of what treatment they actually received. 56 Patients, however, do not always comply with the treatment they were assigned. Because of ethical 57 concerns or other reasons, they may switch treatments from the control group to the experimental 58 group. For example, it may occur when a disease progresses or when the healthcare provider 59 believes the patient's prognosis will improve with the experimental treatment. When treatment 60 switching, also called crossover, is permitted, the ITT analysis is confounded, which decreases the 61 power of a statistical test. A simple and alternative approach, such as the per-protocol analysis, 62 excludes the subjects who switch treatments from the statistical analysis. Nevertheless, this may 63 heavily bias the analysis results if the subjects included and excluded in the analysis significantly 64 differ in prognosis, i.e., treatment switching is associated with prognostic variables [1].

65

66 Various statistical methods dealing with treatment switching have been proposed. Law and Kaldor
67 [2] proposed the adjusted Cox model by splitting the study population into four groups according
68 to their initial and final treatment groups and by assuming different hazard functions with time

69 dependent covariates defined by the time of switching treatment for the four group. Loeys and 70 Goetghebeur [3] proposed the causal proportional hazards estimator by assuming that patients in 71 one arm complete their treatment while the patients in the other arm either completely fulfills their 72 treatment or does not fulfill their treatment at all. Robins and Tsiatis [4] proposed correcting for 73 non-compliance by using the rank preserving structural accelerated failure time models (RPSFT). 74 Based on the RPSFT, Branson and Whitehead [5] and Zhang and Chen [6] provided iterative parametric estimation and modified iterative parametric estimation methods, respectively, for fast 75 76 and reliably estimating the treatment effect. Morden et al. [1] and Latimer et al. [7, 8] performed 77 simulations studies to compare several adjustment methods mentioned above.

78

79 However, sample sizes estimation in most RCTs is still based on the assumption of no treatment 80 switching and predetermined statistical tests, such as the logrank test in ITT analysis. Given the sample sizes estimated from no-switching designs, the ITT analysis may underestimate the positive 81 82 treatment effect when treatment switching occurs. In this study, we proposed a simulation-based 83 approach, PowerSwitchingTrial, to preview power reductions and calculate sample sizes required in RCTs allowing treatment switching. We investigated the impact of the relative effectiveness of 84 85 the experimental treatment to the control, the switching probability, the allocation ratio, and the 86 switching time on power reductions and sample sizes estimation. We found the switching 87 probability and the switching time are key determinants for power decreasing and thus sample 88 sizes increasing to maintain the desired power in ITT analysis. PowerSwitchingTrial is freely 89 available at https://github.com/darwin-hub/PowerSwitchingTrial.

90

92 **2. Methods**

93 2.1 PowerSwtichingTrial overview

94 *PowerSwitchingTrial* is a simulation-based R package, developed for exploring statistical powers and sample sizes required in RCT trials allowing treatment switching when the logrank test is used 95 96 in ITT analysis. The flowchart of PowerSwitchingTrial is shown in Fig. 1. PowerSwitchingTrial simulates a two-arm randomized clinical trial study with an accrual time of T_a and an additional 97 follow-up time of $T_e - T_a$, where T_e is the time from the start to the end of the trial. Participants 98 99 are assumed to enter the study uniformly during the accrual time period, and soon be randomly 100 assigned to one of the two treatment groups, the control group (TX_1) or the experimental group (TX_2) , with an allocation ratio of r $(r = TX_2/TX_1)$. The survival time of subjects in the control and 101 experimental groups, denoted by T_1 and T_2 , is assumed to follow exponential distributions with 102 103 the median value of m_1 and m_2 , respectively. The censoring time of subjects in the two groups, 104 denoted by C_1 and C_2 , is defined as the time from randomization until the end of the trial if the 105 subjects do not experience the event of interest.

106

107 PowerSwtichingTrial allows subjects in the control group have a chance to switch to the 108 experimental group if predetermined conditions are satisfied. For example, if patients with cancer 109 are observed to have a disease progression before death (assume death is the event of interest), 110 they may switch from the standard treatment to the new treatment after disease progression. The 111 switching time, denoted by *s*, is defined as the time from randomization until treatment switching. 112 s is fixed or random, which depends on a practical application. For example, s will be fixed if 113 there is a time set in a clinical trial to switch treatments, while s will be random if the switching time depends on disease progression. In the setting of random s, we assume $s = X \times T_1$, where 114

115 X is a random variable generated from a beta distribution with the parameters of a and b, namely Beta(a,b). The two parameters control the relationship between s and T_1 . Moreover, 116 117 *PowerSwtichingTrial* considers a parameter of *p* (switching probability) to define the probability that a subject who qualifies for treatment switching will switch from TX_1 to TX_2 after evaluations 118 119 from physicians or health care professionals. The survival time for subjects starting from switching 120 is assumed to increase by a constant multiplier of A, based on the rank preserving structural failure time model [4]. That is, the survival time of the subjects with treatment switching will be $T_1^* =$ 121 $s + (T_1 - s) \times A$. Therefore, the observable survival time Y_1 for the subjects who are 122 123 originally assigned to TX_1 will be equal to $min(T_1, C_1)$ without treatment switching, and 124 $min(T_1^*, C_1)$ with treatment switching. The observable survival time Y_2 for the subjects in TX_2 will be equal to $min(T_2, C_2)$. Finally, the logrank test is used to compare Y_1 and Y_2 . 125

126

127 2.2 Two main functions of *PowerSwtichingTrial*

128 PowerSwtichingTrial provides two main functions, LogRankTestMix2PowerMedian and 129 LogRankTestMix2Nmedian. LogRankTestMix2PowerMedian calculates the power, given sample 130 sizes, the difference in the survival time between two groups, and the other parameters. 131 LogRankTestMix2NMedian estimates sample sizes, given an expected power to detect the 132 difference in the survival time between two groups, and the other required parameters.

133

134 LogRankTestMix2PowerMedian, a function to calculate the power, includes 13 input parameters 135 to simulate a number of scenarios, $n, m_1, m_2, r, T_a, T_e, p$, alpha, random, s, a, b, and reps. n is 136 the number of participants in the control group, m_1, m_2, r, T_a, T_e , and the switching probability 137 (p) were defined in Section 2.1, alpha is the significance level, and reps is the number of computer

simulations. The *random* is a logic indicator, FALSE or TRUE. If *random* = FALSE, the switching time is fixed and *s* is required; if *random* = TRUE, the switching time is random and the parameters of *a* and *b* in the beta distribution are required. The function will return the power, that is, the average number of rejecting the null hypothesis which suggests no difference in survival time between the two treatment groups across *reps* simulations.

143

144 LogRankTestMix2Nmedian is a function to calculate the sample sizes. LogRankTestMix2NMedian 145 uses the same parameters as LogRankTestMix2PowerMedian, except the parameter of n that is 146 replaced by power, lower, and upper. Lower and upper is the minimum and maximum sample 147 sizes that users set to explore. The function uses the bisection method to find the sample size (n) 148 required between the initial lower and upper bounds.

149

150

151 **3. Results**

A number of scenarios were generated to explore the effect of treatment switching on powers and sample sizes estimation in ITT analysis, which included the relative different effectiveness of the experimental treatment to the control, the different switching probability, the different allocation ratio, and the fixed/random switching time. In each scenario, the accrual time T_a was set to 3, the study time T_e was set to 5, and m_1 was set to 1. Under no treatment switching, the expected power to detect the survival difference between two treatment groups was set as 0.8 and the significance level was set as 0.05. The number of computer simulations was set at 5,000.

159

160 **3.1** Effect of the relative effectiveness on power and sample sizes estimation

We first investigated the impact of the relative effectiveness of the experimental treatment to the control (m_2/m_1) on power and sample sizes estimation, which ranged at 1.25, 1.5, 1.75, and 2 (Supplementary Tables s1-s3). We found the power decreased and the ratio of sample sizes with treatment switching to those absence of switching (n_s/n_{no-s}) increased slightly with the rising relative effectiveness (Fig. 2). For example, given r = 1, p = 0.4, and s = 0.5, the ratio increased from 1.94 to 2.07 and the power decreased from 0.52 to 0.50 when the relative effectiveness grew from 1.25 to 2 (Supplementary Table s1).

168

169 **3.2** Effect of the switching probability on power and sample sizes estimation

170 We further evaluated the effect the switching probability (p) on power and sample sizes 171 estimation, which was set at 0.2, 0.4, 0.6, 0.8, and 1.0. We found the power decreased and the ratio 172 of sample sizes (n_s/n_{no-s}) increased significantly with the enlarging switching probability (Fig. 173 3). For example, the ratio of sample sizes increased from ~ 1.4 to ~ 11.6 and the power decreased 174 from ~0.7 to ~0.1 When the switching probability increased from 0.2 to 1.0 (Supplementary Table 175 s1). The result indicates that the switching probability is critical for power and sample sizes 176 estimation. A small change of the switching probability would require much more sample sizes to 177 maintain the expected power.

178

179 **3.3** Effect of the allocation ratio on power and sample sizes estimation

180 Moreover, we examined the effect of the allocation ratio (r) on power and sample sizes estimation, 181 which was set at 1 and 2. The sample size required for the control group decreased as the allocation 182 ratio increased from 1 to 2, the total sample size increased though. The ratio of sample sizes 183 (n_s/n_{no-s}) increased slightly but the power didn't show a clear increasing or decreasing pattern.

For example, under s = 0.5, given p = 0.2, the power with r = 1 was larger than that with r = 2. In contrast, the power with r = 1 was smaller than that with r = 2 given p = 1(Supplementary Table s1).

187

188 **3.4** Effect of the switching time on power and sample sizes estimation

189 Finally, we explored the effect of the switching time on power and sample sizes estimation. The 190 switching time (s) was either set at a fixed value or generated by random. The switching time was 191 set at 0.5 and 1 if fixed, otherwise the switching time was generated by a product of survival time 192 of the control group and a random variable from a beta distribution with shape parameters of a =193 2 and b = 2. The mean of the random switching time was 0.5. Overall, the ratios of sample sizes 194 (n_s/n_{n_0-s}) using random switching time were smaller than those using the fixed switching time of 0.5 (Fig. 4 and Supplementary Tables s1 and s2). The ratio of sample sizes (n_s/n_{no-s}) increased 195 196 and power decreased significantly when the fixed switching time moved to an earlier time point 197 (from 1 to 0.5), especially when the switching probability p is greater than 0.6 (Fig.4 and 198 Supplementary Table s1 and s3). For example, the ratio of sample sizes decreased from ~11 to ~3 199 when the switching time moved from 0.5 to 1 under p = 1, r = 1, and m2/m1 = 1.5 (Fig. 4). 200 The results indicated that the switching time is also a key factor for power reductions and sample 201 sizes increase in clinical trials with treatment switching.

202

203 4. Discussion

Our simulation study showed a standard ITT analysis failing to consider treatment switching resulted in a significant reduction of statistical powers especially when the switching probability is high and the switching time is early, which indicated that a much larger sample size was required

to maintain the expected power. The sample sizes required in RCTs absence of treatment switching varied from around three-fourths to one-twelfths of the sample sizes required in RCTs allowing treatment switching as the probability of switched patients increased. The growth of the relative effectiveness and the switching probability increased the ratio of samples and decreased the power, while the later switching time decreased the ratio of sample sizes and increased the power. The allocation ratio was slightly associated with the increasing sample sizes but was not associated with the decreasing power.

214

215 *PowerSwitchingTrial* assumed the effects of the experimental treatment were the same for the 216 subjects switched from TX_1 to TX_2 and those initially assigned to TX_2 , which is the same as the 217 "common treatment effect" assumption made by RPSFTM [8]. In some cases, the assumption may 218 be problematic. The subjects switched from TX_1 to TX_2 may be associated with worse survival. 219 Properly adjusting the accelerated factor *A* may be useful to fit the scenario. Multiplying a constant 220 that is less than 1 to *A* may be a solution, but it is difficult to determine the constant value before 221 clinical trials even if we can borrow the information from previous similar studies.

222

The assumption of exponential distributions for survival time also limits the flexibility and practice of *PowerSwitchingTrial*. Survival times do not always follow exponential distributions well. Weibull or gamma distribution may be alternatives to exponential distributions. However, it is not easy for clinicians to determine a non-exponential distribution with at least two parameters. Median survival or mean survival is still commonly used, which leads to favoring of exponential distributions. In addition, *PowerSwitchingTrial* assumed the censoring time depended only on the entry time and study time although other factors that would cause censoring include a small

proportion of patients dropping out from the study and a loss of follow up. This was due to no needfor additionally assuming a probability distribution for the censoring time.

232

233 The current version of *PowerSwitchingTrial* is built for two-arm RCTs. It can be extended to multi-

arm RCTs, straightforwardly but not simply. More parameters need to be determined in multi-arm

clinical trial designs. We plan to extend *PowerSwitchingTrial* for multi-arm RCTs in the nearfuture.

237

238 5. Conclusions

239 In this study, we proposed a simulation-based approach, PowerSwitchingTrial, to evaluate 240 statistical powers and sample sizes required in RCTs allowing switching in ITT analysis when the 241 logrank test is used. The approach not only provides a preview for power declining but also 242 calculates the required sample size to achieve an expected power when treatment switching occurs. 243 It will provide researchers and clinicians with useful information before RCTs are conducted. 244 245 Abbreviations 246 247 **ITT:** intention-to-treat 248 **RCT:** randomized controlled trials 249 **RPSFT:** rank preserving structural accelerated failure time models 250

251 **Declarations**

252 Ethics approval and consent to participate

- 253 Not applicable.
- 254 Consent for publication
- 255 Not applicable.
- 256 Availability of data and materials
- 257 Additional file 1: Supplementary Tables s1-s3.

258 Competing interests

- 259 The authors declare that they have no competing interests.
- 260 Funding
- 261 This work was supported by the National Institutes of Health [P30CA068485, U24CA163056,
- 262 U24CA213274, P50CA236733, P50CA098131, U54CA163072].
- 263 Authors' contributions
- 264 LD and CYH were major contributors in writing the manuscript and developing the R package.
- 265 YS was the major contributor in the conception and design of the work.

266 Acknowledgements


267 Not applicable.

269 **References**

- 270 1. Morden, JP, Lambert PC, Latimer N, Abrams, KR, Wailoo, AJ. Assessing methods for dealing
- 271 with treatment switching in randomised controlled trials: a simulation study. BMC Medical
- 272 Research Methodology. 2011; 11, 4.
- 273 2. Law, MG, Kaldor, JM. Survival analyses of randomized clinical trials adjusted for patients
 274 who switch treatments. Statistics in Medicine. 1996; 15: 2069-2076.
- Loeys, T, Goetghebeur, E. A Causal Proportional Hazards Estimator for the Effect of
 Treatment Actually Received in a Randomized Trial with All-or-Nothing Compliance.
 Biometrics. 2003; 59: 100-105.
- Robins, JM, Tsiatis, AA. Correcting for non-compliance in randomized trials using rank
 preserving structural failure time models, Communications in Statistics Theory and Methods.
 1991; 20, 2609-2631.
- 5. Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients
 switch treatment, Statistics in Medicine. 2002; 21, 2449-2463.
- 283 6. Zhang J, Chen, C. Correcting treatment effect for treatment switching in randomized oncology
 284 trials with a modified iterative parametric estimation method. Statistics in Medicine. 2016; 35,
 285 3690-3703.
- 286 7. Latimer, NR, Abrams, KR, Lambert, PC, Crowther, MJ, Wailoo, AJ, Morden, JP, et al.
 287 Adjusting for treatment switching in randomised controlled trials a simulation study and a
 288 simplified two-stage method. Statistical Methods in Medical Research. 2017; 26, 724-751.
- 289 8. Latimer, NR, Abrams, KR, Lambert, PC, Morden, JP, Crowther, MJ. Assessing methods for

290 dealing with treatment switching in clinical trials: A follow-up simulation study. Statistical

291 Methods in Medical Research. 2018; 27, 765-784.



296 Figure 1. A flowchart of *PowerSwtichingTrial*.




Figure 2. Effect of relative effectiveness on power (A) and sample sizes estimation (B). s =
0.5.




Figure 3. Effect of switching probability on power (A) and sample sizes estimation (B). s =
0.5.

